Zhu H*#, Wang C*#, Wang J, Chen D, Deng J*#, Deng J, Fan J^, Badakhshi H§, Huang X, Zhang L, Cai J, Guo S, Qian W, Nie Y$, Li Q, Zhao K*#.
A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification
J Thorac Dis 2018; 10(9):5328-38.
*Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University
#Department of Oncology, Shanghai Medical College, Fudan University
^Department of Gynaecology, Renhe Hospital
§Department of Radiation Oncology, Charité School of Medicine and Centre for Cancer Medicine
$State Key Laboratory of Cancer Biology & Xijing Hospital of Digest Diseases, Fourth Military Medical University
Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most esophageal tumors. However, non-selected patient cohorts have shown no response to most EGFR-targeted therapies.
Identifying which esophageal squamous cell carcinoma (ESCC) patients respond to EGFR targeting agents, and a predictive biomarker to stratify clinical cohorts for treatment, would help improve the poor prognosis in ESCC.
This publication investigates the activity of cetuximab in a Mouse Clinical Trial using a cohort of ESCC patient-derived xenograft (PDX) models. PDX have been previously used to predict clinical activity of drugs and explore biomarkers across a range of cancer types.
Download This Publication To Understand:
- That ESCC PDX models recapitulate patient disease preclinically, allowing the investigation of translational biomarkers of response
- How a Mouse Clinical Trial across a cohort of PDX models identified a subset of responders to cetuximab monotherapy
- That gene amplification and expression analysis indicated that high EGFR copy number, high EGFR mRNA expression, and IHC score of 2–3 associate with cetuximab response, indicating EGFR may function as a single predictive biomarker for cetuximab response in ESCC